2021
DOI: 10.3389/fphar.2021.750847
|View full text |Cite
|
Sign up to set email alerts
|

Synergistic Cascade Strategy Based on Modifying Tumor Microenvironment for Enhanced Breast Cancer Therapy

Abstract: Background: Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer with very few treatment options. Although tumor-targeted nanomedicines hold great promise for the treatment of TNBC, the tumor microenvironment (TME) continues to be a major cause of failure in nanotherapy and immunotherapy. To overcome this barrier, we designed a new synergistic cascade strategy (SCS) that uses mild hyperthermia and smart drug delivery system (SDDS) to alter TME resistance in order to improve drug… Show more

Help me understand this report
View preprint versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2022
2022
2023
2023

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 60 publications
0
1
0
Order By: Relevance
“… Liu et al (2022) administered silibinin and curcumin co-loaded nanoparticles into 4T1 tumour-bearing mice and received an excellent response by inhibiting BC metastasis. Zhang et al (2021a) designed a novel synergistic cascade strategy (SCS) that involved the use of mild hyperthermia and a smart drug delivery system (SDDS) to alter TME resistance for the effective therapy of TNBC. Shen et al (2018) engineered, formulated, and delivered genes encoding an IL-10 protein trap to change immunosuppressive TME.…”
Section: Discussionmentioning
confidence: 99%
“… Liu et al (2022) administered silibinin and curcumin co-loaded nanoparticles into 4T1 tumour-bearing mice and received an excellent response by inhibiting BC metastasis. Zhang et al (2021a) designed a novel synergistic cascade strategy (SCS) that involved the use of mild hyperthermia and a smart drug delivery system (SDDS) to alter TME resistance for the effective therapy of TNBC. Shen et al (2018) engineered, formulated, and delivered genes encoding an IL-10 protein trap to change immunosuppressive TME.…”
Section: Discussionmentioning
confidence: 99%